TITLE

Drug Rehab

AUTHOR(S)
Herper, Matthew
PUB. DATE
February 2006
SOURCE
Forbes Asia;2/27/2006, Vol. 2 Issue 3, p56
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the efforts of biotechnology firm Celgene to revive the birth defect-causing drug thalidomide as a potent cancer fighter. Thalidomide is used to treat multiple myeloma, a blood-and-bone-marrow cancer that afflicts 50,000 people in the U.S. Celgene has won approval for its second drug Revlimid, the product of a long-term study to develop a version of thalidomide that would be as potent against cancer but would lack most of thalidomide's side effects. Revlimid is used to treat another form of blood cancer called 5q syndrome.
ACCESSION #
20992637

 

Related Articles

  • Thalidomide.  // Reactions Weekly;3/15/2008, Issue 1193, p27 

    The article presents case reports of nine patients who developed arterial and venous thrombotic complications after receiving thalidomide for multiple myeloma. The patient characteristics are described including their sex, age, thrombosis onset and lesion type. All of them received oral...

  • Thalidomide.  // Reactions Weekly;3/14/2009, Issue 1243, p42 

    The article presents two case studies of women with multiple myeloma who developed hepatotoxicity while receiving thalidomide. The first patient started receiving 28-day cycles of thalidomide 50 mg/day and pulse dexamethasone with weekly thalidomide dosage increases of 50 mg/day to a maximum of...

  • Thalidomide.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p33 

    The article describes the case of a 71-year-old man who developed pneumonitis following the administration of thalidomide for multiple myeloma. The patient became febrile 12 days after receiving thalidomide. Thalidomide and other antibacterial therapy were stopped and the patient's symptoms...

  • Thalidomide.  // Reactions Weekly;4/5/2008, Issue 1196, p36 

    The article describes the case of four patients who developed intestinal perforation during treatment with thalidomide. A 34-year old man with metastatic exocrine porocarcinoma presented with acute abdominal pain after several weeks of treatment with thalidomide and later died during an...

  • Thalidomide.  // Reactions Weekly;Dec2014, Vol. 1531 Issue 1, p168 

    An abstract of the article "Association of melphalan, prednisone and thalidomide (MPT) as upfront therapy in elderly multiple myeloma patients: A monocentric experience," by A. Moscetti and colleagues is presented.

  • Myelosuppression Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board. Miceli, Teresa; Colson, Kathleen; Gavino, Maria; Lilleby, Kathy // Clinical Journal of Oncology Nursing;Jun2008 Supplement, Vol. 12, p13 

    Novel therapies for multiple myeloma include the immunomodulatory drugs lenalidomide and thalidomide and the proteasome inhibitor bortezomib, which have increased response rates and survival times. However, the agents can cause myelosuppression, which, if not managed effectively, can be life...

  • Gastrointestinal Side Effects Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board. Smith, Lisa C.; Bertolotti, Page; Curran, Kathleen; Jenkins, Bonnie // Clinical Journal of Oncology Nursing;Jun2008 Supplement, Vol. 12, p37 

    The novel immunomodulatory drugs lenalidomide and thalidomide and the novel proteasome inhibitor bortezomib can cause gastrointestinal side effects, including constipation, diarrhea, nausea, and vomiting, which can have a deleterious effect on quality of life and interfere with optimal therapy....

  • Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma. Rajkumar, S. Vincent // Mayo Clinic Proceedings;Dec2005, Vol. 80 Issue 12, p1549 

    The article focuses on the significance of the arrival of thalidomide and bortezomib in the treatment of multiple myeloma. Thalidomide is widely used alone or in combination with other active drugs to treat disease. It has multiple proposed mechanisms of action, such as antiangiogenesis, tumor...

  • Thalidomide.  // Reactions Weekly;1/5/2008, Issue 1183, p30 

    The article describes a medical case of a 58-year-old man who developed leukocytoclastic vasculitis during treatment with thalidomide for multiple myeloma. The man started receiving thalidomide at a dosage of 100 milligram (mg) per day increased to 200 mg per day after two weeks. After nine...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics